Actelion Ltd. Miglustat (Zavesca) Receives Negative Opinion From the European Committee For Medicinal Products For Human Use For Extension of Indication For Niemann Pick Type C
ALLSCHWIL, Switzerland, Oct. 19, 2007 (PRIME NEWSWIRE) -- Actelion Ltd (Swiss:ATLN.SW - News) announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion for the extension of indication on the use of miglustat (Zavesca(r)) in patients suffering from Niemann Pick type C (NP-C), a rare genetic disease associated with multiple neurological manifestations.